Details

Autor(en) / Beteiligte

• Di Pardo, Benjamin J.
• Bronson, Nathan W.
• Diggs, Brian S.
• Thomas, Charles R.
• Hunter, John G.
• Dolan, James P.

Titel

The Global Burden of Esophageal Cancer: A Disability-Adjusted Life-Year Approach

Ist Teil von

• World journal of surgery, 2016-02, Vol.40 (2), p.395-401

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Introduction Esophageal cancer is the eighth most common cancer worldwide and the sixth leading cause of cancer-related deaths. As a significant cause of morbidity and mortality, its burden on society has yet to be fully characterized. The aim of this study is to examine its global burden through estimation of the disability-adjusted life years (DALYs) attributable to it. Methods Global incidence and mortality estimates for esophageal cancer were obtained from the International Agency for Research on Cancer GLOBOCAN 2008 database. DALYs were calculated, using methodology established by the World Health Organization. Results In 2008, 3,955,919 DALYs were attributed to esophageal cancer, at a global rate of 0.58 DALYs per 1000 people annually. Years of life lost (YLL) accounted for 96.8 % of DALYs, while years lived with disability (YLD) accounted for 3.2 %. 83.8 % of the global DALYs occurred in less-developed countries, with most accrued in Eastern Asia, comprising 50.9 % of the total. The highest rate of DALY accrual was in Southern Africa, at 1.62 DALYs per 1000 people annually. Conclusions A substantial number of years of life were lost or affected by esophageal cancer worldwide in 2008, with the burden resting disproportionately on less-developed countries. Geographically, the greatest burden is in Eastern Asia. The vast majority of DALYs were due to YLL, rather than YLD, indicating the need to focus resources on disease prevention and early detection. Our findings provide an additional basis upon which to formulate global priorities for interventions that affect DALY reduction in esophageal cancer.